Literature DB >> 2320562

Proteinaceous inhibitors of phospholipase A2 purified from inflammatory sites in rats.

Y Suwa1, I Kudo, A Imaizumi, M Okada, T Kamimura, Y Suzuki, H W Chang, S Hara, K Inoue.   

Abstract

We have purified two phospholipase A2 inhibitory proteins (37 and 33 kDa) from peritoneal fluid of dexamethasone-treated rats. The extracellular phospholipase A2 found in inflammatory sites differed from the exocrine phospholipase A2 in susceptibility to these endogenous inhibitors; both proteins inhibited the activity of the extracellular phospholipase A2 purified from sites of inflammation but did not affect appreciably the activity of either porcine pancreatic or Naja naja venom phospholipase A2. The amino acid sequence of the NH2-terminal portion of the purified proteins did not resemble that of lipocortins so far reported, but it was almost identical to that of parts of human or mouse complement component C3. These findings may indicate that degraded products of C3 are involved in the regulation of activity of a class of mammalian phospholipase A2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320562      PMCID: PMC53695          DOI: 10.1073/pnas.87.7.2395

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Microdetermination of long-chain fatty acids in plasma and tissues.

Authors:  V P DOLE; H MEINERTZ
Journal:  J Biol Chem       Date:  1960-09       Impact factor: 5.157

2.  Inhibition of prostaglandin biosynthesis by corticosteroids requires RNA and protein synthesis.

Authors:  A Danon; G Assouline
Journal:  Nature       Date:  1978-06-15       Impact factor: 49.962

3.  Blockade by antiglucocorticoids, actinomycin D and cycloheximide of anti-inflammatory action of dexamethasone against bradykinin.

Authors:  S Tsurufuji; K Sugio; F Takemasa; S Yoshizawa
Journal:  J Pharmacol Exp Ther       Date:  1980-02       Impact factor: 4.030

4.  Characterization and partial purification of 'renocortins': two polypeptides formed in renal cells causing the anti-phospholipase-like action of glucocorticoids.

Authors:  J F Cloix; O Colard; B Rothhut; F Russo-Marie
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

5.  Stimulation of prostaglandin synthesis by bradykinin and thrombin and their mechanisms of action on MC5-5 fibroblasts.

Authors:  S L Hong; L Levine
Journal:  J Biol Chem       Date:  1976-09-25       Impact factor: 5.157

6.  Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.

Authors:  J L Meuth; E L Morgan; R G DiSipio; T E Hugli
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.

Authors:  A E Davis; R A Harrison; P J Lachmann
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids.

Authors:  F Hirata; E Schiffmann; K Venkatasubramanian; D Salomon; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

9.  Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.

Authors:  U E Nydegger; R H Zubler; R Gabay; G Joliat; C H Karagevrekis; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids.

Authors:  G J Blackwell; R Carnuccio; M Di Rosa; R J Flower; L Parente; P Persico
Journal:  Nature       Date:  1980-09-11       Impact factor: 49.962

View more
  10 in total

1.  Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.

Authors:  W Pruzanski; K Scott; G Smith; I Rajkovic; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

2.  Unusually high conservation of untranslated sequences in cDNAs for Trimeresurus flavoviridis phospholipase A2 isozymes.

Authors:  T Ogawa; N Oda; K Nakashima; H Sasaki; M Hattori; Y Sakaki; H Kihara; M Ohno
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  Comparison of the catalytic properties of phospholipase A2 from pancreas and venom using a continuous fluorescence displacement assay.

Authors:  A Kinkaid; D C Wilton
Journal:  Biochem J       Date:  1991-09-15       Impact factor: 3.857

4.  Suppression of inflammatory responses to 12-O-tetradecanoyl-phorbol-13-acetate and carrageenin by YM-26734, a selective inhibitor of extracellular group II phospholipase A2.

Authors:  A Miyake; H Yamamoto; E Kubota; K Hamaguchi; A Kouda; K Honda; H Kawashima
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

5.  Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.

Authors:  J A Green; G M Smith; R Buchta; R Lee; K Y Ho; I A Rajkovic; K F Scott
Journal:  Inflammation       Date:  1991-10       Impact factor: 4.092

6.  Characterization and pharmacological modulation of soluble phospholipase A2 generated during glycogen-induced rat peritonitis.

Authors:  L A Marshall; J Murphy; L Marinari; J Chang
Journal:  Agents Actions       Date:  1992-09

7.  Are events after endotoxemia related to circulating phospholipase A2?

Authors:  A A Santos; J L Browning; M R Scheltinga; E A Lynch; E F Brown; P Lawton; E Chambers; I Dougas; C D Benjamin; C A Dinarello
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

8.  Phospholipase A2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin: some implications for its functional role.

Authors:  M A Gijón; C Pérez; E Méndez; M Sánchez Crespo
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

9.  Group II phospholipase A(2) in human gingiva with periodontal disease.

Authors:  H Shinohara; T Komatsubara; H Tojo; M Okamoto; S Nishikawa; T Nagata; H Ishida
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

10.  Inhibition of the activity of pro-inflammatory secretory phospholipase A(2) by acute phase proteins.

Authors:  W Pruzanski; E Stefanski; P Vadas
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.